PVI
CLDX icon

Pura Vida Investments’s Celldex Therapeutics CLDX Stock Holding History

Pura Vida Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100,000
Closed -$2.7M – 215
2022
Q2 		$2.7M Buy
+100,000
New +$2.9M 0.16% 122

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Pura Vida Investments's CLDX Position: Q2 2022 in Review

Pura Vida Investments sold out of Celldex Therapeutics (CLDX) in Q2 2022, closing a stake of 132,571 shares — an estimated $3.85M sold.

Pura Vida Investments first reported a position in CLDX in Q2 2020 and held it in 7 quarters. The position peaked at $5.09M in Q4 2021. 157 funds tracked by Wall St. Rank hold CLDX as of Q2 2022.

  • Pura Vida Investments reported no remaining Celldex Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pura Vida Investments sold 132,571 Celldex Therapeutics shares in Q2 2022, an estimated $3.85M.
  • Pura Vida Investments first reported a position in Celldex Therapeutics in Q2 2020 and held it in 7 quarters.
  • Pura Vida Investments's Celldex Therapeutics position peaked at $5.09M in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.